# EGTX PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/EGTX
Company: Egetis

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with EGTX.

## EGTX PDUFA Milestones

- 2026-09-28 — PDUFA — FDA approved Emcitate for MCT8 deficiency. FDA approved Emcitate tablets for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficie...
  Company: Egetis
  Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency
  Event detail: https://biopharmsignal.com/pdufa-calendar/EGTX/emcitate-tiratricol-mct8-deficiency.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/september (September 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/EGTX
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the EGTX PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with EGTX, including decision dates, application stage, and summary details when available.
### Where can I find more context for EGTX?

Use the BioPharmSignal company page for EGTX to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.